Investor Relations

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies that modulate the CXCR4 pathway. Leveraging our unparalleled expertise in diseases of the immune system and CXCR4 biology, we are focused on delivering innovative treatments to people with rare diseases and limited treatment options, including those with certain immunodeficiencies and cancers. While internally we are solely focused on developing our lead candidate, mavorixafor, for chronic neutropenic disorder indications, we are also pursuing partnership opportunities to further advance our oncology programs.